載入...
Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients
Chronic spontaneous urticaria (CSU) affects 1% of the world population and also their quality of life, and 50% of these patients are refractory to H(1)-antihistamines. Omalizumab is a humanized monoclonal anti-IgE antibody that binds with free IgE antibodies and reduces the circulating levels of fre...
Na minha lista:
| 發表在: | Indian Dermatol Online J |
|---|---|
| Main Authors: | , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Medknow Publications & Media Pvt Ltd
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4763587/ https://ncbi.nlm.nih.gov/pubmed/26955580 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2229-5178.174314 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|